Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease

Background: Information on human papillomavirus (HPV) type distribution is necessary to evaluate the potential impact of current and future HPV vaccines. We estimated the relative contribution (RC) to invasive cervical cancer (ICC) and precancerous cervical lesions of the nine HPV types (HPV 6/11/16...

Descripción completa

Detalles Bibliográficos
Autores: Serrano, Beatriz, Alemany i Vilches, Laia, Tous, Sara, Bruni, Laia, Clifford, Gary M ., Weiss, Thomas W., Bosch José, Francesc Xavier, 1947-, Sanjosé Llongueras, Silvia de
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2012
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/126480
Acceso en línea:https://hdl.handle.net/2445/126480
Access Level:acceso abierto
Palabra clave:Papil·lomavirus
Càncer de coll uterí
Papillomaviruses
Cervix cancer
id ES_ee69c3e795d00fd2aab0b70f300bb28a
oai_identifier_str oai:diposit.ub.edu:2445/126480
network_acronym_str ES
network_name_str España
repository_id_str
spelling Potential impact of a nine-valent vaccine in human papillomavirus related cervical diseaseSerrano, BeatrizAlemany i Vilches, LaiaTous, SaraBruni, LaiaClifford, Gary M .Weiss, Thomas W.Bosch José, Francesc Xavier, 1947-Sanjosé Llongueras, Silvia dePapil·lomavirusCàncer de coll uteríPapillomavirusesCervix cancerBackground: Information on human papillomavirus (HPV) type distribution is necessary to evaluate the potential impact of current and future HPV vaccines. We estimated the relative contribution (RC) to invasive cervical cancer (ICC) and precancerous cervical lesions of the nine HPV types (HPV 6/11/16/18/31/33/45/52/58) included in an HPV vaccine currently under development. Methods: Estimations on ICC were based on an international study of 8,977 HPV positive cases and estimations on precancerous cervical lesions were extracted from a published meta-analysis including 115,789 HPV positive women. Globocan 2008 and 2010 World Population Prospects were used to estimate current and future projections of new ICC cases. Results: RC of the 9 HPV types in ICC was 89.4%, with 18.5% of cases positive for HPV 31/33/45/52/58. Regional variations were observed. RCs varied by histology, ranging between 89.1% in squamous cell carcinomas (SCC) and 95.5% in adenocarcinomas (ADC). HPV 16/18/45 were detected in 94.2% of ADC. RC of the 9 types altogether decreased with age (trend test p < 0.0001), driven by the decrease in older ages of HPV 16/18/45. In contrast, the RC of HPV 31/33/52/58 increased with age. Due to population growth alone, projected estimates of ICC cases attributable to the 9 types are expected to rise from 493,770 new cases in 2012 to 560,887 new cases in 2025. The RCs of individual high risk HPV types varied by cytological and histological grades of HPV-positive precancerous cervical lesions, and there was an under representation of HPV 18 and 45 compared to ICC. Conclusions: The addition of HPV 31/33/45/52/58 to HPV types included in current vaccines could prevent almost 90% of ICC cases worldwide. If the nine-valent vaccine achieves the same degree of efficacy than previous vaccines, world incidence rates could be substantially reduced.BioMed Central2012info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/126480Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReproducció del document publicat a: https://doi.org/10.1186/1750-9378-7-38Infectious Agents and Cancer, 2012, vol. 7, num. 38https://doi.org/10.1186/1750-9378-7-38cc by (c) Serrano et al., 2012http://creativecommons.org/licenses/by/3.0/es/info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/1264802026-05-27T06:46:51Z
dc.title.none.fl_str_mv Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease
title Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease
spellingShingle Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease
Serrano, Beatriz
Papil·lomavirus
Càncer de coll uterí
Papillomaviruses
Cervix cancer
title_short Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease
title_full Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease
title_fullStr Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease
title_full_unstemmed Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease
title_sort Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease
dc.creator.none.fl_str_mv Serrano, Beatriz
Alemany i Vilches, Laia
Tous, Sara
Bruni, Laia
Clifford, Gary M .
Weiss, Thomas W.
Bosch José, Francesc Xavier, 1947-
Sanjosé Llongueras, Silvia de
author Serrano, Beatriz
author_facet Serrano, Beatriz
Alemany i Vilches, Laia
Tous, Sara
Bruni, Laia
Clifford, Gary M .
Weiss, Thomas W.
Bosch José, Francesc Xavier, 1947-
Sanjosé Llongueras, Silvia de
author_role author
author2 Alemany i Vilches, Laia
Tous, Sara
Bruni, Laia
Clifford, Gary M .
Weiss, Thomas W.
Bosch José, Francesc Xavier, 1947-
Sanjosé Llongueras, Silvia de
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Papil·lomavirus
Càncer de coll uterí
Papillomaviruses
Cervix cancer
topic Papil·lomavirus
Càncer de coll uterí
Papillomaviruses
Cervix cancer
description Background: Information on human papillomavirus (HPV) type distribution is necessary to evaluate the potential impact of current and future HPV vaccines. We estimated the relative contribution (RC) to invasive cervical cancer (ICC) and precancerous cervical lesions of the nine HPV types (HPV 6/11/16/18/31/33/45/52/58) included in an HPV vaccine currently under development. Methods: Estimations on ICC were based on an international study of 8,977 HPV positive cases and estimations on precancerous cervical lesions were extracted from a published meta-analysis including 115,789 HPV positive women. Globocan 2008 and 2010 World Population Prospects were used to estimate current and future projections of new ICC cases. Results: RC of the 9 HPV types in ICC was 89.4%, with 18.5% of cases positive for HPV 31/33/45/52/58. Regional variations were observed. RCs varied by histology, ranging between 89.1% in squamous cell carcinomas (SCC) and 95.5% in adenocarcinomas (ADC). HPV 16/18/45 were detected in 94.2% of ADC. RC of the 9 types altogether decreased with age (trend test p < 0.0001), driven by the decrease in older ages of HPV 16/18/45. In contrast, the RC of HPV 31/33/52/58 increased with age. Due to population growth alone, projected estimates of ICC cases attributable to the 9 types are expected to rise from 493,770 new cases in 2012 to 560,887 new cases in 2025. The RCs of individual high risk HPV types varied by cytological and histological grades of HPV-positive precancerous cervical lesions, and there was an under representation of HPV 18 and 45 compared to ICC. Conclusions: The addition of HPV 31/33/45/52/58 to HPV types included in current vaccines could prevent almost 90% of ICC cases worldwide. If the nine-valent vaccine achieves the same degree of efficacy than previous vaccines, world incidence rates could be substantially reduced.
publishDate 2012
dc.date.none.fl_str_mv 2012
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/126480
url https://hdl.handle.net/2445/126480
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.1186/1750-9378-7-38
Infectious Agents and Cancer, 2012, vol. 7, num. 38
https://doi.org/10.1186/1750-9378-7-38
dc.rights.none.fl_str_mv cc by (c) Serrano et al., 2012
http://creativecommons.org/licenses/by/3.0/es/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc by (c) Serrano et al., 2012
http://creativecommons.org/licenses/by/3.0/es/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv BioMed Central
publisher.none.fl_str_mv BioMed Central
dc.source.none.fl_str_mv Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869423668497481728
score 15,300719

Similares en LA Referencia